CJC-1295 + Ipamorelin Stack Guide: The Most Popular GH Protocol of 2026
Ask anyone in a peptide forum what their first injectable stack was, and a large portion will say the same thing: CJC-1295 paired with Ipamorelin. This combination has dominated GH optimization protocols for years because it works through two entirely different receptor pathways — and that synergy produces GH pulses significantly higher than either compound alone.
This guide covers everything you need to understand the stack before starting: the science behind why these two compounds are paired, how to dose them correctly, what the realistic timeline looks like, and the single most common mistake people make that kills their results.
What the Stack Is
CJC-1295 is a GHRH (growth hormone-releasing hormone) analogue. It mimics the signal your hypothalamus sends to your pituitary to release GH. Ipamorelin is a ghrelin mimetic — it binds to the ghrelin receptor (GHSR) and triggers GH release through an entirely separate pathway.
The reason these two are combined is simple: they hit different receptors simultaneously. CJC-1295 amplifies the GHRH signal. Ipamorelin triggers release via the ghrelin receptor and suppresses somatostatin — the hormone that inhibits GH secretion. Together, they produce a GH pulse estimated at 3 to 8 times baseline levels, compared to either compound alone.
This isn't theoretical stacking — the dual-pathway mechanism is well-characterized in peptide research and is the reason virtually every modern GH peptide protocol uses some variation of a GHRH + ghrelin mimetic combination.
DAC vs. No-DAC: Which CJC-1295 Are You Actually Using?
This is where a lot of confusion enters the conversation. There are two versions of CJC-1295, and they behave very differently:
CJC-1295 With DAC
The Drug Affinity Complex (DAC) modification covalently binds CJC-1295 to albumin in the bloodstream, dramatically extending its half-life to 8 to 10 days. This means once-weekly dosing is possible, which sounds convenient. The problem: a constant, elevated GHRH signal throughout the week blunts the natural pulsatility of GH release. Your body normally releases GH in pulses — particularly during deep sleep and after exercise. Chronic GHRH elevation disrupts this rhythm.
CJC-1295 No-DAC (Mod GRF 1-29)
The No-DAC version has a half-life of approximately 30 minutes. It mimics the natural GHRH pulse — a sharp rise, then clearance. This is what most protocols use today, and it is what this guide covers. When someone says "CJC-1295" in the context of a daily peptide stack, they almost certainly mean the No-DAC version, also called Mod GRF 1-29.
The short half-life is a feature, not a limitation. It allows you to time your injections precisely around the natural GH release window — primarily before bed — without chronically suppressing your body's own pulsatile rhythm.
Dosing Protocol
| Compound | Dose | Timing | Frequency |
|---|---|---|---|
| CJC-1295 No-DAC | 100 mcg | 30 minutes before bed | Daily |
| Ipamorelin | 100–200 mcg | Same injection | Daily |
| Cycle length | 12 weeks on | 4 weeks off | — |
Both compounds are compatible in the same syringe. Draw your CJC-1295 No-DAC first, then draw Ipamorelin into the same insulin syringe. They are stable when mixed and injected together.
Injection Details
Subcutaneous injection into abdominal fat or the outer thigh. Use a 31-gauge insulin syringe. Pinch an inch or two of fat, insert at 45 degrees, slow plunge. Apply light pressure after withdrawing. Rotate sites to avoid tissue buildup at any single location.
For a complete walkthrough of the injection process, see our subcutaneous injection guide.
What the Research Shows
GH and IGF-1 increases with GHRH + ghrelin mimetic combinations are well-documented in published research. Multiple studies confirm statistically significant elevations in both GH pulse amplitude and IGF-1 serum levels with protocols similar to the one described above.
Body composition changes — reduced fat mass, improved lean mass preservation — are confirmed in research populations, but they require dietary support. Peptides amplify what your diet and training are already doing. They do not replace either. Someone eating in a caloric surplus will use the elevated GH environment to build lean tissue more efficiently. Someone in a mild deficit will preserve muscle while losing fat at a higher rate. Someone eating at maintenance with poor sleep and no training will notice primarily the sleep and recovery benefits.
This is the most important thing to understand before starting: these compounds are tools for the person already doing the fundamentals well.
Realistic Results Timeline
Weeks 1–2
The earliest and most consistent effect is sleep quality. Users report deeper sleep stages, more vivid dreaming (a proxy for REM density), and waking feeling more rested. Workout recovery improves noticeably — DOMS resolves faster, sessions feel better.
Weeks 3–6
Skin hydration and texture improvements become apparent. Joint soreness — particularly chronic, low-grade soreness from training — tends to diminish. GH has direct effects on connective tissue and cartilage that are independent of IGF-1. Some users pair this stack with BPC-157 during this phase for accelerated joint support.
Weeks 8–12
Visible body composition changes for users with diet dialed in. The full IGF-1 elevation effect accumulates over the cycle. This is when training adaptations become most apparent — strength improvements, visible changes in muscle fullness or fat distribution depending on the dietary goal.
Who Benefits Most
Men and women over 35 see the clearest benefit from GH peptide stacks. GH output begins declining meaningfully after approximately age 30, dropping roughly 15% per decade. Someone at 40 may be producing significantly less GH than they were at 25 — and the GH they do produce comes in smaller, less frequent pulses.
A healthy 22-year-old with naturally high GH output will see less dramatic results from this stack than a 42-year-old with age-related GH decline. This doesn't mean younger users see nothing — but the magnitude of effect scales with how far below optimal your baseline GH is.
WADA Status
Both CJC-1295 and Ipamorelin are on the World Anti-Doping Agency prohibited list, classified as GH releasing peptides. Competitive athletes in tested sports should note this before beginning any GH peptide protocol. The off-season / non-competition window does not provide full protection given detection windows for associated biomarkers.
Injecting too close to a meal. Food intake — particularly carbohydrates — spikes insulin, and elevated insulin suppresses GH release. If you inject CJC-1295 + Ipamorelin right after dinner, you are blunting the GH pulse you paid for. The injection window requires at least 2 hours after your last meal and ideally 3. This is why before-bed dosing works: most people have naturally fasted 2 to 3 hours by the time they sleep. If your eating schedule runs late, adjust your injection accordingly. The timing matters as much as the dose.
Pairing With Other Protocols
This stack pairs well with BPC-157 (for joint and gut healing), GHK-Cu (for skin and collagen during the GH-elevated environment), and NAD+ for broader metabolic support. These are not required additions — the CJC-1295 No-DAC + Ipamorelin combination stands alone as a complete first injectable stack.
Ready to get started? The Ipamorelin/CJC-1295 product page covers sourcing details, and our main peptide guide walks through everything from reconstitution to cycle planning for those just beginning their first protocol.